SEOUL, Korea--(BUSINESS WIRE)--SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it has entered into a licensing agreement with Hanmi Pharmacutical Co., Ltd. for SK Biopharmaceuticals’ diazepam nasal spray (DZNS) technology. In signing the deal, Hanmi acquired regional marketing rights for Korea and China. SK Biopharmaceuticals will receive an upfront payment, development and sales milestones, and royalties on sales in return.
